Cargando…

Anti-ADAMTS13 Autoantibodies: From Pathophysiology to Prognostic Impact—A Review for Clinicians

Thrombotic thrombocytopenic purpura (TTP) is a fatal disease in which platelet-rich microthrombi cause end-organ ischemia and damage. TTP is caused by markedly reduced ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity. ADAMTS13 autoantibodies (auto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dainese, Cristina, Valeri, Federica, Bruno, Benedetto, Borchiellini, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488355/ https://www.ncbi.nlm.nih.gov/pubmed/37685697 http://dx.doi.org/10.3390/jcm12175630

Ejemplares similares

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications
por: Dainese, Cristina, et al.
Publicado: (2022)

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
por: Thomas, Mari R., et al.
Publicado: (2015)

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura
por: Kangro, Kadri, et al.
Publicado: (2020)

Impact of COVID-19 Infection, Vaccination, and Serological Response in Immune Thrombocytopenic Purpura Patients: A Single-Center Global Analysis
por: Dainese, Cristina, et al.
Publicado: (2022)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

Generation of potentially inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019
por: Doevelaar, Adrian A. N., et al.
Publicado: (2023)

Management of patients with bleeding disorders and educational needs regarding hemophilia a in 23 Italian emergency departments – Results from a survey conducted in Piedmont
por: Pollio, Berardino, et al.
Publicado: (2022)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
por: Graça, Nuno A. G., et al.
Publicado: (2019)

Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
por: Sinkovits, György, et al.
Publicado: (2018)

Hematologic Chaos in Lupus Flare: A Case of Fulminant and Simultaneous Antiphospholipid, Anti-ADAMTS13, and Red Blood Cell Autoantibodies
por: Al-Mondhiry, Jafar, et al.
Publicado: (2020)

Extended half‐life rFIX in major surgery—How to improve clinical practice: An intraindividual comparison
por: Valeri, Federica, et al.
Publicado: (2020)

Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach
por: Patrick, Tiffany, et al.
Publicado: (2012)

ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
por: Joly, Bérangère S., et al.
Publicado: (2022)

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Bonnez, Quintijn, et al.
Publicado: (2023)

Optimization of anti-ADAMTS13 antibodies for the treatment of ADAMTS13-related bleeding disorder in patients receiving circulatory assist device support
por: Ito, Toshihiro, et al.
Publicado: (2021)

ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012)

Disappearing acts of ADAMTS13
por: Voorberg, Jan, et al.
Publicado: (2015)

Mechanisms of ADAMTS13 regulation
por: DeYoung, Veronica, et al.
Publicado: (2022)

ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice
por: Zitomersky, Naamah L., et al.
Publicado: (2017)

Transforming the major autoantibody site on ADAMTS13: spacer domain variants retaining von Willebrand factor cleavage activity
por: Scully, Marie
Publicado: (2020)

Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational Study
por: Hafez, Wael, et al.
Publicado: (2022)

Systemic antithrombotic effects of ADAMTS13
por: Chauhan, Anil K., et al.
Publicado: (2006)

Reduced ADAMTS13 activity is associated with an ADAMTS13 SNP, fever and microparticles in a malaria-like model
por: Kraisin, Sirima, et al.
Publicado: (2014)

Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13
por: Michael, Mini, et al.
Publicado: (2018)

Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13
por: Michael, Mini, et al.
Publicado: (2018)

Frequency of Pro475Ser Polymorphism of ADAMTS13 Gene and Its Association with ADAMTS-13 Activity in the Korean Population
por: Jang, Mun Ju, et al.
Publicado: (2008)

Further characterization of ADAMTS-13 inactivation by thrombin
por: LAM, J K, et al.
Publicado: (2007)

Association of ADAMTS13 polymorphism with cerebral malaria
por: Kraisin, Sirima, et al.
Publicado: (2011)

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
por: Sarig, Galit
Publicado: (2014)

Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017)

ADAMTS13: An Emerging Target in Stroke Therapy
por: Chen, Xin, et al.
Publicado: (2019)

Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity
por: Ercig, Bogac, et al.
Publicado: (2021)

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis
por: Uemura, Masahito, et al.
Publicado: (2011)

Novel mutations in ADAMTS13 CUB domains cause abnormal pre‐mRNA splicing and defective secretion of ADAMTS13
por: Jiang, Yizhi, et al.
Publicado: (2020)

Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality
por: Karim, Farheen, et al.
Publicado: (2013)

Assaying ADAMTS13 Activity as a Potential Prognostic Biomarker for Sinusoidal Obstruction Syndrome in Mice
por: Saeki, Masakazu, et al.
Publicado: (2023)

The role of autoantibodies in the pathophysiology of rheumatoid arthritis
por: Derksen, V. F. A. M., et al.
Publicado: (2017)

Phenotypic Expression of ADAMTS13 in Glomerular Endothelial Cells
por: Tati, Ramesh, et al.
Publicado: (2011)

Conformational quiescence of ADAMTS‐13 prevents proteolytic promiscuity
por: South, K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d1q3jhaccrp5r2jgc6q6e77f56